Výsledky vyhledávání - "C. M. BROOME"

Akademický článek

S285: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2-YEAR FOLLOW-UP FROM THE CARDINAL STUDY

Autor: A. Röth, W. Barcellini, S. D’Sa, Y. Miyakawa, C. M. Broome, M. Michel, D. J. Kuter, B. Jilma, T. H. A. Tvedt, I. C. Weitz, T. Sourdille, J. Wang, D. S. Vagge, K. Kralova, F. Shafer, M. Wardecki, M. Lee, S. Berentsen

Publikováno v: HemaSphere, Vol 6, Pp 186-187 (2022)

Externí odkaz: https://doaj.org/article/a34cde245dfb45c88f1f16f61df2f2aa

Zobrazit plný text záznamu

Akademický článek

S304: SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2 YEAR FOLLOW-UP FROM THE CARDINAL STUDY

Autor: A. Röth, C. M. Broome, W. Barcellini, T. Henrik Anderson Tvedt, Y. Miyakawa, S. D’Sa, D. Cella, F. Joly, J. Wang, T. Sourdille, F. Shafer, M. Wardęcki, I. C. Weitz

Publikováno v: HemaSphere, Vol 6, Pp 205-206 (2022)

Externí odkaz: https://doaj.org/article/d5db73f054814d97ba53a8b11c22a523

Zobrazit plný text záznamu

Akademický článek

P1538: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK WASHOUT PERIOD IN PHASE 3 CARDINAL STUDY (NCT03347396)

Autor: A. Röth, W. Barcellini, S. D’Sa, Y. Miyakawa, C. M. Broome, M. Michel, D. J. Kuter, B. Jilma, T. H. A. Tvedt, I. C. Weitz, T. Sourdille, J. Wang, D. S. Vagge, K. Kralova, F. Shafer, M. Wardecki, M. Lee, S. Berentsen

Publikováno v: HemaSphere, Vol 6, Pp 1419-1420 (2022)

Externí odkaz: https://doaj.org/article/23936ed5d9b745278637508147336ab0

Zobrazit plný text záznamu

Lenalidomide following rituximab and fludarabine in untreated CLL

Autor: Philip R. Cohen, Chaitra S. Ujjani, Saad Jamshed, Bruce D. Cheson, C. M. Broome, Edmund A. Gehan, Jenny Crawford, Craig M. Kessler, K. W. Fitzpatrick

Publikováno v: Journal of Clinical Oncology. 29:6558-6558

6558 Background: The combination of fludarabine (F) and rituximab (R) has shown an ORR of 90% (CR 47%) in pts with untreated CLL. Nevertheless, relapse is inevitable. Lenalidomide (L) has shown an ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56ec753dc3267b2f843b748359f15217
https://doi.org/10.1200/jco.2011.29.15_suppl.6558

Zobrazit plný text záznamu

Autor: C. M. BROOME, L. L. LESSIN

Publikováno v: JNCI Journal of the National Cancer Institute. 84:268-268

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cb19ac8fe63de234ad19831edae0cd5
https://doi.org/10.1093/jnci/84.4.268-a

Zobrazit plný text záznamu